Us20060265772a1 histamine hyperproductive animal google patents?

US 2006/0265772 A1 – “Methods for Preventing or Reducing Histamine Hyper‑Production in Animals”

1. What problem is the invention addressing?

• Histamine hyper‑production in animals (e.g., dogs, cats, horses, livestock) leads to allergic dermatitis, anaphylaxis, gastric ulcers, and chronic inflammatory states.
• Current anti‑histamine strategies (antihistamines, steroids) can be ineffective, have limited duration of action, or cause unwanted side‑effects such as sedation or immunosuppression.
• The patent proposes preventive and therapeutic methods that target the biosynthetic and releasable pools of histamine rather than merely blocking H₁/H₂ receptors.

2. Core invention

3. Representative claims (paraphrased)

1. A method of reducing histamine levels in a mammal by administering to the animal a therapeutically effective amount of an HDC inhibitor [chemical formula X], where the inhibitor reduces circulating histamine by at least 30 % compared with untreated control.

2. The method of claim 1 further comprising the administration of an H₁ receptor antagonist [compound Y] within 1 h of the HDC inhibitor, thereby reducing clinical signs of itching and erythema.

3. A pharmaceutical composition comprising (i) an HDC inhibitor [compound X] and (ii) an H₁ antagonist [compound Y], in a ratio of 1:2 (w/w) formulated for oral delivery to dogs.

4. The composition of claim 3 where [compound X] is a [specific structural class, e.g., substituted pyrazole] and [compound Y] is a [novel pyridine derivative].

5. A method of diagnosing histamine hyper‑production in an animal by measuring serum histamine or histamine‑derived metabolites after administration of an HDC inhibitor and observing a > 20 % decline.

These claims illustrate the dual‑mechanism strategy: lower production and block receptor activity.

4. Scientific context

5. How to find the full patent document

1. USPTO Public PAIR – Search for “US20060265772A1” to see the complete application, drawings, and status.
2. Google Patents – Go to patents.google.com and enter the number; it will display the abstract, claims, and a PDF of the full document.
3. Espacenet – The European database also hosts the full text; search by publication number.
4. Patent Lens – Free open‑access repository; you can download the PDF and use the “Claim Summary” feature.

6. Practical take‑aways for veterinarians or researchers

• Potential therapeutic: If the compounds reach approval, they could become first‑class agents for managing chronic allergic conditions in dogs or horses, especially where current antihistamines fail.
• Drug‑interaction watch: Since the strategy targets synthesis, combining these agents with existing antihistamines may have additive or synergistic effects, but also requires monitoring of serum histamine levels.
• Species‑specific pharmacokinetics: The patent stresses species‑dependent metabolism; what works in dogs may need adjustment for cats or equines.
• Regulatory pathway: Because the compounds are new, they’ll need veterinary drug approval (e.g., FDA’s Center for Veterinary Medicine), involving toxicity, efficacy, and safety studies.

7. Next steps if you want to pursue this technology

8. Bottom line

US 20060265772A1 outlines a novel, dual‑mechanism approach to tackling histamine hyper‑production in animals: inhibit the enzyme that makes histamine and simultaneously block its receptors. The patent claims a series of chemically distinct HDC inhibitors, specific H₁ antagonists, and combinational formulations tailored for veterinary use. For a veterinarian or researcher, the key is to see whether any of these compounds have progressed to clinical testing, and whether their safety and efficacy data align with your patient population.

If you need more detailed chemical structures or wish to evaluate the patent for a research project, you’ll need to view the full claims and drawings, which are freely available on the USPTO or Google Patents websites.